Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » Exelixis, NCI to Study Anti-Cancer Compounds

Exelixis, NCI to Study Anti-Cancer Compounds

Jun 07, 2000
Premium

SOUTH SAN FRANCISCO--Exelixis announced that it has signed a Cooperative Research and Development Agreement with the US National Cancer Institute to elucidate how NCI anti-cancer compounds work. In the three-year collaboration, Exelixis will use its proprietary model system genetics technology to identify the mechanism of action for NCI compounds that have a demonstrated in vivo or in vitro anti-cancer activity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
26
Featured Webinar

Robust CNV Detection Using Whole-Exome Sequencing for Complex Cases

Sponsored by
Sophia Genetics

This webinar will discuss Genotypos Science Labs’ experience with a whole-exome sequencing solution supporting the detection of copy number variants (CNVs) for the management of complex cases.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

What's Popular?

In Informatics

  1. Kaiser Permanente Taps BC Platforms to Analyze Biobank, Clinical Data

    Premium

  2. Hexagon Bio Raises $47M in Series A Round

  3. Japanese Startup BitBiome Builds Single-Cell Bacterial Sequencing Services Business

    Premium

  4. LabCorp's Covance Joins Tempus TIME Trial Program

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.